About: Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro
Creator	Wu, Yan Zhang, Jing Sun, Yuan Gong, Rui Shi, Jian Pan, Xiaoyan Shang, Weijuan Xiao, Gengfu Chen, Ze Jiang, Xiaming Fan, Tiejiong Fang, Lijuan Shi, Xiaoyue Zhao, Shaojuan Zhou, Pengfei
Source	BioRxiv
abstract	COVID-19 caused by the emerging human coronavirus, SARS-CoV-2, has become a global pandemic, leading a serious threat to human health. So far, there is none vaccines or specific antiviral drugs approved for that. Therapeutic antibodies for SARS-CoV-2, was obtained from hyper immune equine plasma in this study. Herein, SARS-CoV-2 RBD with gram level were obtained through Chinese hamster ovary cells high-density fermentation. The binding of RBD to SARS-CoV-2 receptor, human ACE2, was verified and the efficacy of RBD in vivo was tested on mice and then on horses. As a result, RBD triggered high-titer neutralizing antibodies in vivo, and immunoglobulin fragment F(ab’)2 was prepared from horse antisera through removing Fc. Neutralization test demonstrated that RBD-specific F(ab’)2 inhibited SARS-CoV-2 with EC50 at 0.07 μg/ml, showing a potent inhibitory effect on SARS-CoV-2. These results highlights as RBD-specific F(ab’)2 as therapeutic candidate for SARS-CoV-2.
has issue date	2020-04-09(xsd:dateTime)
bibo:doi	10.1101/2020.04.07.029884
has license	biorxiv
sha1sum (hex)	eff1e4662c359f503831cf32cc1f15df34db4eef
schema:url	https://doi.org/10.1101/2020.04.07.029884
resource representing a document's title	Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro
schema:publication	bioRxiv
resource representing a document's body	covid:eff1e4662c359f503831cf32cc1f15df34db4eef#body_text
is schema:about of	named entity 'equine' named entity 'immune' named entity 'highlights' named entity 'Immunoglobulin' named entity 'REMOVING' named entity 'NEUTRALIZING ANTIBODIES' named entity 'IMMUNOGLOBULIN FRAGMENT' named entity 'PANDEMIC' named entity 'FERMENTATION' named entity 'MICE' named entity 'ANTIVIRAL DRUGS' named entity 'THERAPEUTIC' named entity 'THREAT' named entity 'CAUSED BY' covid:arg/eff1e4662c359f503831cf32cc1f15df34db4eef named entity 'cells' named entity 'immunoglobulin' named entity 'SARS-CoV-2' named entity 'receptor' named entity 'These' named entity 'coronavirus' named entity 'vivo' named entity 'SARS-CoV-2' named entity 'caused' named entity 'inhibited' named entity 'plasma' named entity 'triggered' named entity 'neutralizing antibodies' named entity 'SARS-CoV-2' named entity 'plasma' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'fermentation' named entity 'Neutralization test' named entity 'human coronavirus' named entity 'global pandemic' named entity 'titer' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'subcutaneous' named entity 'virus' named entity 'affinity chromatography' named entity 'COVID' named entity 'immunogen' named entity 'organism' named entity 'H1N1' named entity 'RBD' named entity 'human plasma' named entity 'F(ab')2' named entity 'quarantine' named entity 'RBD' named entity 'antibody' named entity 'ADE' named entity 'immunization' named entity 'F(ab')2' named entity 'immunization' named entity 'immunization' named entity 'passaged' named entity 'SARS-CoV-2' named entity 'CHO cells' named entity 'ADE' named entity 'qRT-PCR' named entity 'F(ab')2' named entity 'vaccines' named entity 'RBD' named entity 'SARS-CoV-2' named entity 'ELISAs' named entity 'immunization' named entity 'SARS-CoV' named entity 'PBS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software